This agreement allows the companies to develop a total of eight ‘discovery phase’ candidates by combining an equal number of programmes.
It also permits both the companies to exclusively license others’ development-ready programmes at pre-determined stages and as share all development costs.
Under the agreement, the companies will co-develop the assets arising out of this collaboration and share all development costs.
Endo Pharma will retain the marketing rights in North America, while Orion will have marketing rights in Europe and Russia.
The companies will pay cross royalties to each other based on sales from their respective territories, and will mutually decide on the most effective method to maximize product opportunities in rest of world (ROW) territories following Phase II studies and share ROW revenues.
Following this partnership, Endo has licensed the lead asset in this collaboration discovered at Orion, a novel androgen-receptor antagonist for the treatment of advanced prostate cancer.